title: Major adverse cardiac events in patients with hepatitis C infection treated with bare-metal versus drug-eluting stents.
abstract: BACKGROUND
  There are no data comparing the long-term outcome of bare-metal stents (BMS) vs drug-eluting stents (DES) in patients with hepatitis C virus (HCV) infection.
  
  
  OBJECTIVE
  In patients with HCV infection, the rate of major adverse cardiac events (MACE) would be less, and the mortality rates similar, in patients treated with DES than in patients treated with BMS.
  
  
  METHODS
  The incidence of major adverse cardiac events (MACE) during long-term follow-up, including death, myocardial infarction, and target-vessel revascularization, was investigated in HCV-infected patients who also underwent percutaneous coronary intervention with bare-metal or drug-eluting stents.
  
  
  RESULTS
  Of 78 patients studied, BMS were placed in 41 patients and DES stents in 37 patients. Stepwise Cox regression analyses were performed to identify significant independent risk factors for MACE. At 42 +/- 11-month follow-up, MACE occurred in 9 of 41 patients (22%) in the BMS group (mean age 63 +/- 11 years, 66% men) vs in 7 of 37 patients (19%) in the DES group (mean age 61 +/- 9 years, 65% men). There was no significant difference in MACE in the BMS group vs the DES group. This persisted even after controlling for length of the stent, complexity of lesion, and other comorbidities. All-cause mortality was not significantly different in the BMS group vs the DES group (7% vs 5%).
  
  
  CONCLUSIONS
  At long-term follow-up of HCV-infected patients with stable liver function, the rates of MACE and of all-cause mortality were similar in the BMS and DES groups.
authors.affiliation: Department of Medicine, Division of Cardiology, New York Medical College, Valhalla, New York 10595, USA. drpchandrasekar@gmail.com
authors.forename: Chandrasekar
authors.initials: C
authors.lastname: Palaniswamy
authors.forename: Wilbert S
authors.initials: WS
authors.lastname: Aronow
authors.forename: Rishi
authors.initials: R
authors.lastname: Sukhija
authors.forename: Tarun
authors.initials: T
authors.lastname: Chugh
authors.forename: Navi
authors.initials: N
authors.lastname: Ramdeen
authors.forename: Kumar
authors.initials: K
authors.lastname: Kalapatapu
authors.forename: Melvin B
authors.initials: MB
authors.lastname: Weiss
authors.forename: Anthony L
authors.initials: AL
authors.lastname: Pucillo
authors.forename: Craig E
authors.initials: CE
authors.lastname: Monsen
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation* / Q000401:mortality; D016009:Chi-Square Distribution; D003324:Coronary Artery Disease / Q000150:complications / Q000401:mortality / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D006526:Hepatitis C / Q000150:complications* / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D008099:Liver / Q000503:physiopathology / Q000821:virology; D008297:Male; D008670:Metals; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology* / Q000401:mortality; D009518:New York; D016016:Proportional Hazards Models; D011474:Prosthesis Design; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D015607:Stents; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D008670:Metals